ProPSA, un nuevo biomarcador para la detección y el manejo del cáncer de próstata

Filella, Xavier; Foj, LAura; Alcover, Joan; Augé, Josep M; Escudero, José M; Molina, Rafael.
Rev. lab. clín ; 6(2): 75-81, abr.-jun. 2013. tab, ilus
Artículo en Español | IBECS (España) | ID: ibc-112746

Documentos relacionados

  1. SERS-Temperature Dual-Mode T-type Lateral Flow Strip for Accurate Detection of Free and Total Prostate-Specific Antigens in Blood.
  2. Short-term prognosis of low-risk prostate cancer patients is favorable despite the presence of pathological prognostic factors: a retrospective study.
  3. Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer.
  4. Preanalytical stability of molecular forms of prostate-specific antigen in serum samples (PSA, free PSA, [-2]proPSA) and their impact on fPSA/tPSA ratio and PHI.
  5. Urinary exosomal prostate-specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles.
  6. Development of an optical microfiber immunosensor for prostate specific antigen analysis using a high-order-diffraction long period grating.
  7. NIR-II-Absorbing TMB Derivative for 1064 nm-Excited Photothermal Immunoassay.
  8. Colorimetric and Photothermal Dual-Modal Switching Lateral Flow Immunoassay Based on a Forced Dispersion Prussian Blue Nanocomposite for the Sensitive Detection of Prostate-Specific Antigen.
  9. New biomarkers for diagnosis and prognosis of localized prostate cancer.
  10. Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence.